MDNA News and Press, Medicenna Therapeutics Corp. From 08/09/22

CorMedix CRMD -61% after FDA again rejects CorMedix's application for lead candidate DefenCath . Turtle Beach HEAR -32% on Q2 earnings miss . Novavax NVAX -31% on Q2 earnings release . Medicenna Therapeutics MDNA -29% on launch of units offeri...

Medicenna Therapeutics ( NASDAQ: MDNA ) shares fell 6% in Monday's extended session after the immunotherapy company announced the launch of an underwritten public offering of units in the U.S. Each unit will be comprised of one common share and one warrant to purchase ...

TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today the launch of a marketed underwritten public offering of uni...

TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 15, 2022 at 8:30 AM ET...

-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s low and mid-stage dose escalation cohorts -- Study’s fifth dose-escalation cohort is open for enrollment foll...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re diving into all the latest stock market news with a breakdown of the biggest pre-market stock movers for Thursday! Moving stocks this morning is merger news, right ...

Medicenna Therapeutics Corp. (MDNA) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Martin Bexon - CMO Liz Williams - CFO Conference Call Participants Matt Biegler - Oppenheimer David Martin -...

Medicenna Therapeutics press release (NASDAQ:MDNA): FY GAAP EPS of -C$0.42. The increase in net loss Y/Y was primarily a result of increased expenditures related to the MDNA11 development program as well as higher general and administrative expenses associated with the Company’s Nasdaq...

--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients enrolled in first 3 dose escalation cohorts of the ABILITY Phase 1/2 Study. -- Pharmacodynamic data show superior dose-dependent increase in stimu...

Medicenna Therapeutics (NASDAQ:MDNA) said the U.S. Patent and Trademark Office granted a patent to the company related to composition and methods to treat degenerative diseases via administration of a fusion protein comprising an IL-4 or IL-13 Superkine and an anti-apoptotic Bcl-2 family...